Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center

The combination of rituximab, lenalidomide, and Bruton’s tyrosine kinase inhibitor (BTKi) ibrutinib, followed by chemotherapy, has shown high efficacy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in Smart Start trial. We aimed to evaluate the efficacy, safety of SMART (ritu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yanan, Zhang, Xiang, Wei, Juying, Yang, Chunmei, Tong, Hongyan, Mai, Wenyuan, Yang, Min, Qian, Jiejing, Mao, Liping, Meng, Haitao, Jin, Jie, Yu, Wenjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479281/
https://www.ncbi.nlm.nih.gov/pubmed/36114573
http://dx.doi.org/10.1186/s40164-022-00314-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479281/
https://www.ncbi.nlm.nih.gov/pubmed/36114573
http://dx.doi.org/10.1186/s40164-022-00314-w

Ejemplares similares